Press Releases

Adamas Appoints New Chief Financial Officer
Jun 28, 2017

Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
Jun 12, 2017

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
Jun 8, 2017

Adamas to Present at Two Upcoming Investor Conferences
Jun 1, 2017

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
May 22, 2017

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
May 11, 2017

Adamas Reports Inducement Grant to New Chief Operating Officer
May 5, 2017

Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
May 2, 2017

Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
Apr 27, 2017

Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease
Apr 24, 2017